Mediolanum International Funds Ltd Acquires 8,474 Shares of ResMed Inc. $RMD

Mediolanum International Funds Ltd grew its holdings in ResMed Inc. (NYSE:RMD) by 14.7% during the third quarter, Holdings Channel.com reports. The firm owned 66,135 shares of the medical equipment provider’s stock after acquiring an additional 8,474 shares during the period. Mediolanum International Funds Ltd’s holdings in ResMed were worth $17,926,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. SJS Investment Consulting Inc. grew its holdings in ResMed by 1,433.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 86 shares during the last quarter. WFA of San Diego LLC acquired a new position in shares of ResMed during the second quarter worth approximately $26,000. GoalVest Advisory LLC acquired a new position in shares of ResMed during the third quarter worth approximately $37,000. Winnow Wealth LLC bought a new stake in shares of ResMed during the third quarter valued at approximately $54,000. Finally, Harbour Investments Inc. increased its holdings in shares of ResMed by 264.2% in the second quarter. Harbour Investments Inc. now owns 244 shares of the medical equipment provider’s stock valued at $63,000 after purchasing an additional 177 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other ResMed news, Director Witte Jan De sold 2,055 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $255.00, for a total value of $524,025.00. Following the transaction, the director directly owned 4,261 shares of the company’s stock, valued at approximately $1,086,555. The trade was a 32.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $248.83, for a total transaction of $497,660.00. Following the transaction, the director directly owned 66,773 shares in the company, valued at approximately $16,615,125.59. This represents a 2.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 21,594 shares of company stock valued at $5,403,495 over the last 90 days. Company insiders own 0.65% of the company’s stock.

Key Headlines Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q2 results beat consensus — GAAP diluted EPS of $2.68 (non‑GAAP $2.81) vs. Street estimates ~ $2.68, revenue $1.423B (+11% YoY), 320 bps gross‑margin improvement and $340M operating cash flow. These metrics support near‑term earnings credibility and cash generation. Read More.
• Positive Sentiment: Board declared a quarterly cash dividend of $0.60 per share (record Feb 12; payable Mar 19), signaling capital return commitment and supporting income investors. Read More.
• Positive Sentiment: Product/innovation catalysts: FDA cleared an AI‑enabled device (“Smart Comfort”) to personalize CPAP settings — strengthens digital/AI positioning and could boost adherence and recurring device/accessory demand. Read More.
• Positive Sentiment: Wells Fargo nudged its price target to $270 (from $265) with an “equal weight” rating — a modest analyst lift that implies limited near‑term upside from that shop. Read More.
• Neutral Sentiment: Analyst landscape remains mixed but generally favorable — several firms maintain outperform/buy views and available median targets sit materially above current price, leaving room for differing investor expectations. Read More.
• Neutral Sentiment: Company hosted the Q2 webcast and transcripts are posted — useful for hearing management’s guide/comments on demand, supply and margin outlook. Read More.
• Negative Sentiment: Expenses rose: SG&A and R&D both increased (~12% YoY) and the company recorded $6M in restructuring charges; higher operating costs could pressure margins if growth slows. Read More.
• Negative Sentiment: Notable insider selling activity was reported in recent months (multiple sales by senior executives), which some investors view as a modest governance/conviction caution. Read More.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on RMD shares. Royal Bank Of Canada boosted their target price on ResMed from $311.00 to $314.00 and gave the stock an “outperform” rating in a research report on Friday. Piper Sandler increased their price objective on shares of ResMed from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Friday. Citigroup restated a “buy” rating on shares of ResMed in a research note on Monday. Morgan Stanley set a $305.00 price target on shares of ResMed in a research report on Friday, October 31st. Finally, KeyCorp restated an “overweight” rating and issued a $302.00 price objective on shares of ResMed in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $297.91.

ResMed Stock Up 0.1%

Shares of NYSE:RMD opened at $257.76 on Monday. The business has a fifty day simple moving average of $251.04 and a 200 day simple moving average of $263.37. ResMed Inc. has a 12-month low of $199.92 and a 12-month high of $293.81. The firm has a market cap of $37.62 billion, a P/E ratio of 25.50, a P/E/G ratio of 1.72 and a beta of 0.87. The company has a quick ratio of 2.32, a current ratio of 3.06 and a debt-to-equity ratio of 0.06.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, January 29th. The medical equipment provider reported $2.81 EPS for the quarter, beating the consensus estimate of $2.68 by $0.13. ResMed had a return on equity of 25.20% and a net margin of 27.53%.The business had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.40 billion. During the same period in the prior year, the business posted $2.43 earnings per share. The firm’s revenue was up 11.0% on a year-over-year basis. Analysts predict that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Thursday, February 12th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Thursday, February 12th. ResMed’s dividend payout ratio (DPR) is presently 23.74%.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.